Ascendis Pharma A/S ASND 深 沪
等待开盘 07-08 09:30:00 美东时间
266.97
-0.950
-0.35%
华盛通- 最 高273.80
- 今 开269.86
- 成交量 62.76万股
- 最 低 266.65
- 昨 收 267.92
- 总市值 175.11亿
- 52周最高 274.89
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 160.86
- 委 比 35.51%
- 总股本 6559.28万
- 历史最高 274.89
- 量 比 0.93
- 振 幅 2.67%
- 历史最低 11.92
- 每 手 1
- 风险率 21.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $280
RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $275 to $280.
07-07 23:59
Ascendis Pharma Closes Warrant Exercise Window, Expands Share Capital
The latest update is out from Ascendis Pharma ( ($ASND) ). On June 29, 2026, As...
06-30 04:28
Ascendis Pharma Announces It Has Been Added To Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 And Russell Midcap
Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution,...
06-27 04:03
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
Ascendis Pharma A/S has been added to several Russell U.S. Indexes, including the Russell 3000, 1000, 2500, and Midcap Indexes, effective June 26, 2026. These indexes track major U.S. equities and are widely used by investors. The company, a global biopharmaceutical firm, applies its TransCon technology to develop innovative therapies. For more information, visit their website or contact investor and media relations.
06-26 20:01
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
Ascendis Pharma announced that data from its clinical trials for treating children with achondroplasia will be presented at the 12th International Conference on Children's Bone Health in Montreal. Key highlights include Week 104 results from the ApproaCH Trial showing improvements in lower-extremity alignment with TransCon CNP (navepegritide) and Week 52 data from the COACH Trial on combination therapy with TransCon CNP and TransCon hGH (lonapegs...
06-25 20:01
Why Is Ascendis Pharma Stock Gaining Friday?
Ascendis Pharma A/S (NASDAQ:ASND) on Thursday reported five-year results from its Phase 2 PaTH Forward trial, showing that TransCon PTH (palopegteriparatide) delivered sustained efficacy and safety in adults with hypoparathyroidism. The stock rose in Friday trading following the announcement. The Pa...
06-13 00:29
Ascendis boasts of long-term Yorvipath data for hypoparathyroidism
Ascendis Pharma (ASND) said that new data from a phase 2 trial of its adult hypoparathyroidism treatment Yorvipath (palopegteriparatide) indicate sustained efficacy over five years. The hormone replac...
06-12 04:31
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
Ascendis Pharma A/S announced that it will present new data on its rare endocrine disease programs, including hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency, at ENDO 2026 in Chicago. The company will share findings through two oral presentations and three posters, highlighting the long-term safety and efficacy of its innovative therapies. Ascendis emphasizes its commitment to advancing treatments for rare diseases thr...
06-08 20:59
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
Citigroup Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $355
Citigroup analyst Eric Joseph initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $355.
05-19 22:31
